Boston Common Asset Management LLC Has $16.02 Million Stock Position in Roche Holding AG $RHHBY

Boston Common Asset Management LLC cut its stake in shares of Roche Holding AG (OTCMKTS:RHHBY) by 5.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 322,354 shares of the company’s stock after selling 17,039 shares during the period. Roche accounts for about 1.0% of Boston Common Asset Management LLC’s investment portfolio, making the stock its 28th biggest holding. Boston Common Asset Management LLC’s holdings in Roche were worth $16,024,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in the stock. S&CO Inc. raised its stake in shares of Roche by 163.0% during the 1st quarter. S&CO Inc. now owns 140,551 shares of the company’s stock worth $6,880,000 after purchasing an additional 87,107 shares in the last quarter. Meritage Portfolio Management acquired a new stake in shares of Roche in the 4th quarter valued at approximately $4,372,000. Hantz Financial Services Inc. grew its stake in shares of Roche by 164.9% in the fourth quarter. Hantz Financial Services Inc. now owns 79,732 shares of the company’s stock valued at $4,112,000 after buying an additional 49,633 shares in the last quarter. Enterprise Financial Services Corp grew its stake in shares of Roche by 6.6% in the first quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock valued at $277,000 after buying an additional 345 shares in the last quarter. Finally, Archer Investment Corp increased its holdings in Roche by 7.7% during the first quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock worth $278,000 after buying an additional 398 shares during the last quarter.

Wall Street Analysts Forecast Growth

RHHBY has been the topic of several analyst reports. HSBC lowered shares of Roche from a “buy” rating to a “hold” rating in a research report on Monday, July 6th. Argus upgraded shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. Morgan Stanley upgraded shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price objective on the stock in a research note on Friday, April 24th. Finally, Zacks Research cut shares of Roche from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $51.50.

Roche Price Performance

Shares of OTCMKTS RHHBY opened at $51.60 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72. Roche Holding AG has a 12 month low of $37.51 and a 12 month high of $60.85. The stock has a 50 day moving average of $51.35 and a 200-day moving average of $52.68.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.